

Resource Summary Report

Generated by NIF on Jul 29, 2026

Somatostatin Receptor 5 antibody [UMB4]

RRID:AB_10859946

Type: Antibody

Proper Citation

Abcam Cat# ab109495, RRID:AB_10859946

Antibody Information

URL: http://antibodyregistry.org/AB_10859946

Proper Citation: Abcam Cat# ab109495, RRID:AB_10859946

Target Antigen: Somatostatin Receptor 5 antibody [UMB4]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry - fixed; Immunocytochemistry; Immunohistochemistry; Western Blot; ICC, IHC-P, WB

Antibody Name: Somatostatin Receptor 5 antibody [UMB4]

Description: This monoclonal targets Somatostatin Receptor 5 antibody [UMB4]

Target Organism: rat, mouse, human

Antibody ID: AB_10859946

Vendor: Abcam

Catalog Number: ab109495

Record Creation Time: 20250819T234140+0000

Record Last Update: 20250820T060737+0000

Ratings and Alerts

No rating or validation information has been found for Somatostatin Receptor 5 antibody [UMB4].

No alerts have been found for Somatostatin Receptor 5 antibody [UMB4].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cosma GM, et al. (2025) Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response. Scientific reports, 15(1), 40706.

Mitsui Y, et al. (2024) Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly. Pituitary, 27(5), 527.

Campana C, et al. (2024) Digital quantification of somatostatin receptor subtypes 2 and 5 in GH-secreting pituitary tumors. European journal of endocrinology.

Gliga MC, et al. (2024) Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. International journal of molecular sciences, 25(16).

Peltola E, et al. (2023) Immunohistochemical somatostatin receptor expression in insulinomas. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 131(4), 152.

Henriques DG, et al. (2023) miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. International journal of molecular sciences, 24(3).

Lutsenko A, et al. (2022) Circulating Plasma MicroRNA in Patients With Active Acromegaly. The Journal of clinical endocrinology and metabolism, 107(2), 500.

Faria O, et al. (2022) Characterization of sporadic somatotropinomas with high GIP receptor expression. Pituitary, 25(6), 903.

Ilie MD, et al. (2022) Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study. The Journal of clinical endocrinology and metabolism, 107(11), 2982.

Amar?? J, et al. (2021) Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. Cancers, 13(8).